Is Collegium Pharmaceutical Stock a Good Investment?
Collegium Pharmaceutical Investment Advice | COLL |
- Examine Collegium Pharmaceutical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Collegium Pharmaceutical's leadership team and their track record. Good management can help Collegium Pharmaceutical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Collegium Pharmaceutical's business and its evolving consumer preferences.
- Compare Collegium Pharmaceutical's performance and market position to its competitors. Analyze how Collegium Pharmaceutical is positioned in terms of product offerings, innovation, and market share.
- Check if Collegium Pharmaceutical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Collegium Pharmaceutical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Collegium Pharmaceutical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Collegium Pharmaceutical is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Collegium Pharmaceutical Stock
Researching Collegium Pharmaceutical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 7.28. The company had not issued any dividends in recent years.
To determine if Collegium Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Collegium Pharmaceutical's research are outlined below:
| Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Collegium Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from gurufocus.com: Insider Sell Colleen Tupper Sells Shares of Collegium Pharmaceutical Inc |
Collegium Pharmaceutical Quarterly Accounts Payable |
|
Collegium Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Collegium Pharmaceutical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Collegium Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Collegium Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Collegium Pharmaceutical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-27 | 2019-12-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2019-08-07 | 2019-06-30 | -0.17 | -0.14 | 0.03 | 17 | ||
2023-08-03 | 2023-06-30 | 0.29 | 0.34 | 0.05 | 17 | ||
2019-05-08 | 2019-03-31 | -0.24 | -0.29 | -0.05 | 20 | ||
2015-08-12 | 2015-06-30 | -0.29 | -0.34 | -0.05 | 17 | ||
2019-11-06 | 2019-09-30 | -0.12 | -0.18 | -0.06 | 50 | ||
2023-02-23 | 2022-12-31 | -0.14 | -0.21 | -0.07 | 50 | ||
2020-08-05 | 2020-06-30 | 0.31 | 0.23 | -0.08 | 25 |
Know Collegium Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Collegium Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Collegium Pharmaceutical backward and forwards among themselves. Collegium Pharmaceutical's institutional investor refers to the entity that pools money to purchase Collegium Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Emerald Advisers, Llc | 2024-12-31 | 811.7 K | Geode Capital Management, Llc | 2024-12-31 | 770.5 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 679.3 K | Massachusetts Financial Services Company | 2024-12-31 | 604.2 K | Emerald Mutual Fund Advisers Trust | 2024-12-31 | 569.6 K | Victory Capital Management Inc. | 2024-12-31 | 559.5 K | Lsv Asset Management | 2024-12-31 | 390.5 K | Northern Trust Corp | 2024-12-31 | 385.2 K | Charles Schwab Investment Management Inc | 2024-12-31 | 367.4 K | Blackrock Inc | 2024-12-31 | 5.6 M | Eventide Asset Management, Llc | 2024-12-31 | 2.6 M |
Collegium Pharmaceutical's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 949.29 M.Market Cap |
|
Collegium Pharmaceutical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.15 | 0.15 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.30 | 0.32 |
Determining Collegium Pharmaceutical's profitability involves analyzing its financial statements and using various financial metrics to determine if Collegium Pharmaceutical is a good buy. For example, gross profit margin measures Collegium Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Collegium Pharmaceutical's profitability and make more informed investment decisions.
Evaluate Collegium Pharmaceutical's management efficiency
Collegium Pharmaceutical has return on total asset (ROA) of 0.0889 % which means that it generated a profit of $0.0889 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3262 %, meaning that it created $0.3262 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.12 this year. Return On Capital Employed is expected to rise to 0.15 this year. At this time, Collegium Pharmaceutical's Return On Tangible Assets are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.67 this year, although the value of Total Current Assets will most likely fall to about 268.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.09 | 7.45 | |
| Tangible Book Value Per Share | (25.56) | (24.28) | |
| Enterprise Value Over EBITDA | 10.08 | 10.59 | |
| Price Book Value Ratio | 4.04 | 5.12 | |
| Enterprise Value Multiple | 10.08 | 10.59 | |
| Price Fair Value | 4.04 | 5.12 | |
| Enterprise Value | 1.7 B | 1.8 B |
The decision-making processes within Collegium Pharmaceutical are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.992 |
Basic technical analysis of Collegium Stock
As of the 27th of March, Collegium Pharmaceutical shows the Risk Adjusted Performance of 0.0161, mean deviation of 1.71, and Downside Deviation of 1.9. Collegium Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Collegium Pharmaceutical downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Collegium Pharmaceutical is priced correctly, providing market reflects its regular price of 29.96 per share. Given that Collegium Pharmaceutical has jensen alpha of 0.0199, we suggest you to validate Collegium Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.Collegium Pharmaceutical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Collegium Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Collegium Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Collegium Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Collegium Pharmaceutical's Outstanding Corporate Bonds
Collegium Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Collegium Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Collegium bonds can be classified according to their maturity, which is the date when Collegium Pharmaceutical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Collegium Pharmaceutical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Collegium Pharmaceutical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0161 | |||
| Market Risk Adjusted Performance | 0.0474 | |||
| Mean Deviation | 1.71 | |||
| Semi Deviation | 1.86 | |||
| Downside Deviation | 1.9 | |||
| Coefficient Of Variation | 9039.77 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.71 | |||
| Information Ratio | 0.0082 | |||
| Jensen Alpha | 0.0199 | |||
| Total Risk Alpha | 0.0262 | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.0374 | |||
| Maximum Drawdown | 18.67 | |||
| Value At Risk | (3.02) | |||
| Potential Upside | 3.47 | |||
| Downside Variance | 3.59 | |||
| Semi Variance | 3.46 | |||
| Expected Short fall | (1.91) | |||
| Skewness | 2.7 | |||
| Kurtosis | 13.71 |
| Risk Adjusted Performance | 0.0161 | |||
| Market Risk Adjusted Performance | 0.0474 | |||
| Mean Deviation | 1.71 | |||
| Semi Deviation | 1.86 | |||
| Downside Deviation | 1.9 | |||
| Coefficient Of Variation | 9039.77 | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.71 | |||
| Information Ratio | 0.0082 | |||
| Jensen Alpha | 0.0199 | |||
| Total Risk Alpha | 0.0262 | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.0374 | |||
| Maximum Drawdown | 18.67 | |||
| Value At Risk | (3.02) | |||
| Potential Upside | 3.47 | |||
| Downside Variance | 3.59 | |||
| Semi Variance | 3.46 | |||
| Expected Short fall | (1.91) | |||
| Skewness | 2.7 | |||
| Kurtosis | 13.71 |
Consider Collegium Pharmaceutical's intraday indicators
Collegium Pharmaceutical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Collegium Pharmaceutical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 5787.67 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 29.96 | |||
| Day Typical Price | 29.96 | |||
| Price Action Indicator | (0.1) | |||
| Period Momentum Indicator | (0.19) | |||
| Relative Strength Index | 49.77 |
Collegium Pharmaceutical Corporate Filings
F4 | 24th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 19th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of March 2025 Other Reports | ViewVerify |
Collegium Stock media impact
Far too much social signal, news, headlines, and media speculation about Collegium Pharmaceutical that are available to investors today. That information is available publicly through Collegium media outlets and privately through word of mouth or via Collegium internal channels. However, regardless of the origin, that massive amount of Collegium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Collegium Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Collegium Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Collegium Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Collegium Pharmaceutical alpha.
Collegium Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Collegium Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Collegium Pharmaceutical Historical Investor Sentiment
Investor biases related to Collegium Pharmaceutical's public news can be used to forecast risks associated with an investment in Collegium. The trend in average sentiment can be used to explain how an investor holding Collegium can time the market purely based on public headlines and social activities around Collegium Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Collegium Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Collegium Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Collegium Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Collegium Pharmaceutical.
Collegium Pharmaceutical Corporate Management
| Shirley JD | General VP | Profile | |
| Bart Dunn | Executive Development | Profile | |
| Scott Sudduth | Head Operations | Profile | |
| Christopher MD | Vice Relations | Profile | |
| Marlo Manning | Head HR | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 1.86 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Collegium Pharmaceutical's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.